Read the report: Providence clinical research innovations

The Providence Research Network (PRN) is pleased to announce the publication of the PRN 2023 Annual Report. The report highlights the exemplary and lifesaving work from our researchers across the Providence family of organizations. From the evaluation of an immunotherapy for non-small cell lung cancer at Providence Cancer Institute of Oregon, to the study of clinical factors of early-onset colon cancer at Providence Saint John’s Cancer Institute, to expansion of minimally invasive treatment for heart valve disease at the Swedish Heart & Vascular Institute, this report represents the tireless work from our researchers, scientists and caregivers throughout 2023. Read the PRN 2023 Annual Report.

Research from PRN reflects the diverse experiences, contexts and needs of all individuals and delivers on the promise to not only study the world, but to help change it. We are grateful and blessed for the brilliant minds across our organization who are championing research to help our patients achieve optimal health outcomes. We graciously thank the principal investigators, the research nurses, the research coordinators, the regulatory specialists, the data gurus, and many more who are dedicated to this work for our most vulnerable patients.  

We would also like to acknowledge Clinical Trials Day, observed May 20. Clinical Trials Day, organized by the Association of Clinical Research Professionals, is an opportunity to pause in reflection, recognition and admiration of all that has been accomplished thanks to clinical trials and the people behind them. You can learn more about clinical trials at Providence and how to enroll in one here.  

About the Author

The inScope content team focuses on bringing you the latest in clinical news from our team of world-class medical providers and physician leaders.

More Content by Providence inScope Content Team
Previous Article
Inhibiting an inhibitor: NIH-funded study targets galectin-3 protein
Inhibiting an inhibitor: NIH-funded study targets galectin-3 protein

A new investigator-initiated study for patients with metastatic melanoma and HNSCC aims to evaluate a galec...

Next Article
Noteworthy - May 2024
Noteworthy - May 2024